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Abstract
Background: The reliability of intrathoracic impedance monitoring for prediction of heart failure 
(HF) by implantable cardiac devices is controversial. Despite using additional device-based parameters 
described in the PARTNERS HF study, such as new onset of arrhythmias, abnormal autonomics, low 
biventricular pacing rate or patient activity level, the predictive power of device diagnostic algorithm is 
still in doubt. The objective of this study was to compare the device diagnostic algorithm described in the 
PARTNERS HF study to a newly developed algorithm applying refined diagnostic criteria.
Methods: Fourty two patients were prospectively enrolled who had been implanted with an intrathoracic 
impedance and remote monitoring capable implantable cardiac defibrillator with a cardiac resychroniza-
tion therapy (CRT-D) device in this observational study. If a remote OptiVolTM alert occurred, patients 
were checked for presence of HF symptoms. A new algorithm was derived from the original PARTNERS 
HF criteria, considering more sensitive cut-offs and changes of patterns of the device-based parameters.
Results: During an average follow-up of 38 months, 722 remote transmissions were received. From 
the total of 128 transmissions with OptiVol alerts, 32 (25%) corresponded to true HF events. Upon 
multivariate discriminant analysis, low patient activity, high nocturnal heart rate, and low CRT pacing 
(< 90%) proved to be independent predictors of true HF events (all p < 0.01). Incorporating these three 
refined criteria in a new algorithm, the diagnostic yield of OptiVol was improved by increasing specific-
ity from 37.5% to 86.5%, positive predictive value from 34.1% to 69.8% and area under the curve from 
0.787 to 0.922 (p < 0.01), without a relevant loss in sensitivity (96.9% vs. 93.8%).
Conclusions: A refined device diagnostic algorithm based on the parameters of low activity level, high 
nocturnal heart rate, and suboptimal biventricular pacing might improve the clinical reliability of  
OptiVol alerts. (Cardiol J 2018; 25, 2: 236–244)
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Introduction
Unfavourable prognostic impacts of recurrent 
hospitalizations in chronic systolic heart failure (HF) 
are well known [1]. Accordingly, several methods 
have been developed aiming at early detection of 
worsening HF with the potential for timely inter-
vention to prevent hospitalizations and improve sur-
vival. Some of the cardiovascular implantable elec-
tronic devices offer extended monitoring capabilities 
of vital parameters which may help to predict HF 
events. Yu et al. [2] developed a detection algorithm 
called OptiVolTM to predict cardiac decompensation 
by applying Fluid Index derived from the changes 
of intrathoracic impedance, as a marker of lung fluid 
status. However, the reliability of OptiVol remained 
contradictory in further clinical trials [3, 4]. In the 
prospective multicenter PARTNERS HF study (Pro-
gram to Access and Review Trending Information 
and Evaluate Correlation to Symptoms in Patients 
with Heart Failure study), the clinical utility of im-
pedance monitoring could have been improved by 
using a combined device diagnostic algorithm based 
on additional parameters such as: new onset of atrial 
fibrillation (AF), rapid ventricular rate during AF, low 
patient activity levels, high night heart rate (HR), 
low heart rate variability (HRV), low percentage of 
biventricular pacing, and ventricular arrhythmias 
with implantable cardioverter-defibrillator (ICD) 
shocks [5, 6]. In this trial the strongest predictor 
was the elevated Fluid Index (i.e. OptiVolTM alert). 
Although the applied device diagnostic algorithm 
could predict the following hospitalization with high 
probability, only in 213 of 1324 (16.1%) high-risk 
periods proved to be associated with true HF events. 
In further studies the number of false positive or 
unexplained OptiVol alerts also remained remark-
ably high despite the combination with remote 
monitoring technics [7–10].
It was thus hypothesized that the reliability of 
OptiVol alerts could be improved with some modifica-
tions of the original PARTNERS HF criteria which 
considering more sensitive diagnostic values and 
changes of patterns in these parameters. In the pre-
sent observational study, the aim was to compare the 
clinical applicability of device diagnostic algorithm de-
scribed in PARTNERS HF study to a newly developed 
algorithm which applies refined diagnostic criteria.
Methods
Study patients and study design
All consecutive patients implanted with an 
OptiVol and wireless telemetry capable implant-
able cardiac defibrillator with cardiac resychroni-
zation therapy (CRT-D) device (Medtronic Inc., 
Minneapolis, MN, US) in the Medical Center of 
Hungarian Defence Forces and signed to be fol-
lowed up via the CareLink® remote monitoring 
system (Medtronic Inc., Minneapolis, MN, US) 
were prospectively recruited from April 2011 to 
June 2014. The optional function of intrathoracic 
impedance monitoring (OptiVol) was activated in 
all patients with an automatic remote alert, if the 
Fluid Index reaches 60 Ω-day. 
Patients were followed up at our outpatient HF 
clinic every 3 months or if clinically indicated. In-
office device control was performed semi-annualy 
by electrophysiologists. The transmitted CareLink 
data were evaluated by an electrophysiologist and 
HF specialist team weekly and within 24 h for 
clinically relevant alerts.
If an OptiVol alert occurred, all device moni-
tored parameters were recorded and patients were 
interviewed by an independent HF specialist for the 
presence of HF symptoms via telephone calls and 
during additional outpatient visits, as necessary. 
An OptiVol alert was categorized as true positive 
(verified HF event) when signs and symptoms of 
decompensated HF required an increase in diuretic 
dose in an outpatient setting or hospitalization.
All patients signed an informed consent form. 
The study complies with the Declaration of Hel-
sinki, and the study protocol was approved by the 
Institutional Ethics Committee.
Assessment of original  
PARTNERS HF criteria
The original PARTNERS HF criteria were 
evaluated for all OptiVol alerts (Fluid Index 
≥ 60 Ω-day) using a time-frame window of 20 days 
prior to an alert, and the sensitivity and specificity 
of the original PARTNERS HF device diagnostic 
algorithm were determined.
New device diagnostic  
algorithm development
A refined diagnostic algorithm was derived 
from an OptiVol alert (Fluid Index ≥ 60 Ω-day) 
and the presence of further positive parameters in 
a 20 day time-frame window prior to the alert. The 
following modified diagnostic criteria were utilized:
 — new AF episode: ≥ 6 h on at least 1 day;
 — high ventricular rate during AF: average ven-
tricular rate during AF ≥ 90 bpm on at least 24 h;
 — lower patient activity level for at least 5 days:
• –2 h/day, if the prior average was ≥ 4 h/day, 
• –1 h/day, if the prior average was < 4 h/day,
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• except (parameter was defined negative), 
if prior average was permanently under 
1 h/day or activity decline was related to 
extracardiac reason (e.g. elective surgery, 
musculoskeletal disorders etc.);
 — elevated nocturnal HR: average night HR 
> 85 bpm or elevated with ≥ 20 bpm to the 
prior average for at least 5 consecutive days;
 — low HRV: < 60 ms every day for 1 week, 
except (parameter was defined negative), if 
permanently under 60 ms;
 — low biventricular pacing rate: < 90% for at 
least 5–7 days, except (parameter was defined 
negative), if permanently < 90%;
 — ventricular arrhythmias: treated by 1 or more 
ICD shocks or successful anti-tachycardia 
pacing.
The differences between the original PART-
NERS HF criteria and these refined parameters are 
highlighted in Table 1. The utilized modifications 
are mainly derived from clinical experience with 
the device based diagnostic.
Statistical analysis
Statistical analyses were performed using 
STATISTICA version 10.0 (Tulsa, Oklahoma, 
USA), SAS version 9.4 (SAS Institute Inc., Cary, 
NC, USA) and MedCalc version 14.12.0 (Ostend, 
Belgium) software. Numerical values are pre-
sented as mean ± standard deviation. Multivari-
ate discriminant analysis was used to assess the 
association between device based parameters and 
the progression of HF. Parameters independently 
associated with true HF events (p < 0.05) were 
included in the final risk score. The predictive 
power of the original and refined clinical algorithms 
was described with sensitivity, specificity, positive 
and negative predictive statistics and the receiver 
operating characteristic method (ROC analysis). 
To obtain an unbiased ROC analysis (training and 
validation was performed on the same popula-
tion) cross-validation was performed. The cross-
validation of ROC curves and confidence interval 
calculations were performed with SAS software by 
the “Proc Logistic” procedure. 
Table 1. Definition of the refined diagnostic criteria and differences to the original PARTNERS HF  
parameters.
Device measured  
parameter
Original PARTNERS HF 
criteria
Refined PARTNERS HF  
criteria
New AF episode AF ≥ 6 h on at least  
1 day without  
persistent AF
AF ≥ 6 h on at least 1 day without persistent AF
Ventricular rate during AF AF ≥ 24 h and daily  
average ventricular rate 
during AF ≥ 90 bpm, on 
at least 24 h 
AF ≥ 24 h and daily average ventricular rate during  
AF ≥ 90 bpm, on at least 24 h
Patient activity level Average activity  
< 1 h over 7 days
Lower average activity over 5 days with
•	–2 h/day, if the prior average was ≥ 4 h/day
•	–1 h/day, if the prior average was < 4 h/day 
•	except, if prior average was permanently < 1 h/day  
or activity decline for extracardiac reason (e.g. elective 
surgery, any musculoskeletal disorders etc.)
Nocturnal heart rate Average night heart rate 
> 85 bpm for  
7 consecutive days 
Average night heart rate > 85 bpm or elevated  
with ≥ 20 bpm to the prior average for at least  
5 consecutive days
Heart rate variability < 60 ms every day  
for 1 week
< 60 ms every day for 1 week, except if permanently  
under 60 ms
Biventricular pacing rate < 90% for 5 of 7 days < 90% for 5 of 7 days, except if permanently < 90%
Ventricular arrhythmias ≥ 1 shocks during the 
evaluation period
≥ 1 shocks or ATPs during the evaluation period
AF — atrial fibrillation; ATP — anti-tachycardia pacing; PARTNERS HF — Program to Access and Review Trending Information and Evaluate 
Correlation to Symptoms in Patients with Heart Failure study
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Results
Patient cohort and clinical characteristics
The average follow-up of the 42 enrolled pa-
tients was 38.0 ± 23.6 months. Detailed patient 
baseline data are summarized in Table 2. It should 
be highlighted that all patients (100%) were on 
beta-receptor blockers and 45.2% of them received 
the maximum recommended dose.
Five patients died, 2 underwent heart trans-
plantation, 1 required an assist device implantation 
and in 1 case the CRT-D system had to be explanted 
due to infection.
OptiVol alerts and heart failure events
Altogether 722 remote transmissions were 
received during the follow-up period. After the 
exclusion of 8 transmissions due to the unavail-
ability of HF specialist adjudication 128 trans-
missions with OptiVol alerts (Fluid Index ≥ 60 
Ω-day) were included in this analysis. Verified HF 
events were observed in 32 (25%) cases (Fig. 1) 
with need for hospitalization in 8 cases. For the 
remaining cases no clinical events were identified 
or clear extracardiac causes were found in the back-
ground of OptiVol alerts (typically infection of the 
upper/lower respiratory tract, acute exacerbation 
of chronic obstructive pulmonary disease, surgery 
for any reason). 
Assessment of the original PARTNERS HF  
criteria in our patient population
The classic PARTNERS HF diagnostic algo-
rithm was positive in 31 of 32 cases with true dete-
rioration of HF (sensitivity 96.9%, 95% confidence 
interval [CI] 83.8–99.9; negative predictive value 
[NPV] 97.3%, 95% CI 85.8–99.9), however, the 
Table 2. Baseline characteristics.
Total 42
Demographics:
Age [years] 64.0 ± 11.7
Gender (male) 81.0%
Heart failure etiology:
Ischemic 57.1%
Non-ischemic: 42.9%
Valvular 4.8%
Non-compaction cardiomyopathy 2.4%
Toxic 2.4%
Myocarditis 9.5%
DCM/Genetic/Unknown 23.8%
Indication for defibrillator implantation:
Primary prevention 78.6%
Secondary prevention 21.4%
Characteristics:
LVEF [%] 26.9 ± 6.1
NYHA class 2.42 ± 0.78
LBBB [%] 76.2
QRS duration [ms] 151 ± 24
Comorbidities:
Atrial fibrillation paroxysmal 40.5%
Atrial fibrillation permanent 23.8%
Diabetes mellitus 38.1%
Hypertension 85.7%
Hyperlipidaemia 26.2%
Chronic pulmonary disease 16.7%
History of CKD* 59.5%
Laboratory values at baseline:
Creatinine [μmol/L] 124.8 ± 52.7
Hemoglobin [g/L] 128.8 ± 17.0
Cardiovascular medication:
Beta-blockers 100.0%
ACEI/ARB 92.9%
Diuretics 83.3%
MRA 78.6%
Nitrates and dihydralazine 81.0%
Antiplatelet therapy 59.5%
Oral anticoagulants 64.3%
Statins 76.2%
Amiodarone 19.0%
Digoxin 11.9%
*GFR < 60 mL/min; ACEI — angiotensin converting enzyme inhibi-
tor; ARB — angiotensin II receptor antagonists; CKD — chronic  
kidney diesease; DCM — dilated cardiomyopathy; LBBB — left 
bundle branch block; LVEF — left ventricular ejection fraction;  
MRA — mineralocorticoid receptor antagonists; NYHA — New  
York Heart Association functional classification
Figure 1. Flowchart of CareLink transmissions during 
the study period; HF — heart failure.
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specificity remained very low with 60 false posi-
tive events (specificity 37.5%, 95% CI 27.8–48.0%; 
positive predictive value [PPV] 34.1%, 95% CI 
24.5–44.7) (Table 3).
Assessment of the new device  
diagnostic algorithm
In multivariate discriminant analysis of the 
refined diagnostic criteria, lower activity levels, 
increased nocturnal HR, and suboptimal biventricu-
lar pacing proved to be independent predictors for 
cardiac decompensation (Table 4).
Applying our refined algorithm which includes 
OptiVol alert events (Fluid Index ≥ 60 Ω-day) and 
the presence of at least one of the aforementioned 
modified diagnostic criteria the number of false 
positive alerts decreased from 60 to 13 (specific-
ity 86.5%, 95% CI 78.0–92.6%; PPV 69.8%, 95% 
CI 53.9–82.8%) without compromising the sen-
sitivity (sensitivity 93.8%, 95% CI 79.2–99.2%; 
NPV 97.6%, 95% CI 91.8–99.7%) (Table 3). The 
diagnostic yield of the modified OptiVol algorithm 
Table 3. Prognostic characteristics of the original and the refined diagnostic criteria.
PARTNERS HF classic  
(without OptiVol ≥ 100)
OptiVol + 1  
modified criteria
Sensitivity (95% CI) 96.9% (83.8–99.9) 93.8% (79.2–99.2)
Specificity (95% CI) 37.5% (27.8–48.0) 86.5% (78.0–92.6)
Positive predictive value (95% CI) 34.1% (24.5–44.7) 69.8% (53.9–82.8)
Negative predictive value (95% CI) 97.3% (85.8–99.9) 97.6% (91.8–99.7)
ROC-analysis/AUC (95% CI)* 0.787 (0.704–0.869) 0.922 (0.869–0.974)
AUC with validation (95% CI)† 0.679 (0.568–0.790) 0.858 (0.767–0.948)
*p between the two algorithms < 0.01; †p between the two algorithms < 0.01 
AUC — area under the curve; CI — confidence interval; PARTNERS HF — Program to Access and Review Trending Information and  
Evaluate Correlation to Symptoms in Patients with Heart Failure study; ROC-analysis — receiver operating characteristic method
Table 4. Results of the multivariate discriminant analysis.
Device measured parameters Wilks’ lambda Partial lambda P
New AF episode 0.421 0.986 0.19
Elevated HR during AF 0.422 0.996 0.47
Patient activity 0.663 0.638 < 0.001
Elevated nocturnal HR 0.485 0.871 < 0.001
Decreased HR variability 0.428 0.989 0.23
Biventricular pacing < 90% 0.532 0.795 < 0.001
ICD therapy (ATP/shock) 0.424 0.9784 0.1
AF — atrial fibrillation; ATP — anti-tachycardia pacing; HR — heart rate; ICD — implantable cardioverter defibrillator
Figure 2. Comparison of receiver operating character-
istic (ROC) curves: classic PARTNERS HF vs. modified 
diagnostic algorithm.
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assessed with ROC-analysis was also improved 
when compared to the classic PARTNERS HF diag-
nostic algorithm (AUC 0.787, 95% CI 0.704–0.869 
vs. AUC 0.922, 95% CI 0.869–0.974, p < 0.01) 
(Table 3, Fig. 2).
On cross-validation of the ROC-curves the dif-
ference between the two algorithms remained sig-
nificant (AUC 0.679, 95% CI 0.568–0.790 vs. AUC 
0.858, 95% CI 0.767–0.948, p < 0.01) (Table 3). 
Discussion
Main results
In this prospective, long-term follow-up study 
of optimally treated HF patients with remote 
monitoring capable CRT-D devices, the diagnostic 
yield of OptiVol alerts could be improved using 
a newly developed diagnostic algorithm based on 
the original PARTNERS HF criteria.
In this new diagnostic algorithm, the modi-
fication of the original PARTNERS HF criteria 
included the refinement of cut-off values and the 
exclusion of cases with permanent positivity of 
the assessed parameters. Lower activity levels, 
increased nocturnal HR, and suboptimal biventricu-
lar pacing proved to be predictors for HF events. 
Prognostic parameters
Patient activity measured by cardiac implant-
able electronic devices were evaluated alone 
[11–13] or together with other diagnostics [5, 6] in 
previous studies. Conraads et al. [11] demonstrated 
that higher levels of physical activity early after de-
fibrillator implantation was associated with better 
outcomes in terms of mortality and HF hospitaliza-
tion. In a single-center study of 164 CRT recipients 
both 6-min walk test and device-based measures 
of higher physical activity predicted reverse re-
modeling and HF hospitalizations [12]. In a recent, 
large-volume observational study derived from 
the ALTITUDE registry, device-detected activity 
strongly correlated with survival [13]. Several 
comorbidities and clinical factors (such as chronic 
obstructive lung disease, elective surgery, muscu-
loskeletal disorders, etc.) were not taken into ac-
count in these analyses, however, these conditions 
could strongly influence the physical activity. This 
study tried to eliminate these confounding factors 
with the modification of the original criterion to 
exclude cases, where the prior average was < 1 h/ 
/day permanently or activity decline was related to 
an extra cardiac reason. 
Elevated HR is thought to be a marker of path-
ological autonomic response and correlates with 
worse prognoses in HF [14]. Post-hoc-analyses of 
BEAUTIFUL and SHIFT studies have confirmed 
the prognostic importance of HR [15, 16]. In the 
observational study of Adamson et al. [17], night-
time HR was higher in CRT recipients who were 
hospitalized or died, compared with those with 
only minor exacerbations or those without any 
HF events. 
According to the current guidelines CRT pac-
ing rate should be as close to 100% as possible. 
The clinical benefit is strongly associated with 
a higher percentage of biventricular pacing as 
demonstrated in several reports [18]. Decrease 
in CRT pacing (< 80% over 48 h) was also one 
of the most frequent findings in the telemetry 
data, leading to additional follow-up visits in the 
IN-TIME study [19]. This randomised, controlled, 
multi-center study could demonstrate that remote 
monitoring (thoracic impedance measurements 
were not included) could improve mortality over 
standard care.
Non-prognostic parameters
The overall low specificity of the original 
PARTNERS HF algorithm may reflect the low 
clinical relevance of some parameters that were 
used. Consistently positive parameters such as 
long-term low patient activity level, long-standing 
low HRV, or persistently low percentage of biven-
tricular pacing prior to an event do not play a role in 
prediction. These parameters represent the clinical 
status of the patient, but do not have enough predic-
tive power to identify clinical events occurring in 
the subsequent few weeks. Therefore, the change 
but not the absolute value of these parameters may 
have significantly greater clinical relevance during 
the index period. 
Although several clinical data suggest that 
HRV can have an inverse correlation with the 
progression of HF [17] and could improve with 
CRT [20], we strongly believe that this parameter 
(HRV in patients treated with CRT) is responsible 
for several false positive cases when applying the 
classic PARTNERS HF criteria. In patients on 
beta-blockers with a maximum tolerated dose, 
a high percentage of atrial pacing is frequently 
present, making the HRV calculation useless or 
misleading. Even in cases of permanent AF, the 
value of HRV should be expected permanently 
under 60 ms, but it does not necessarily mean an 
unstable clinical condition. Figure 3 illustrates 
a case with an increase in HRV, while the patient 
status worsened because of an increase in heart 
rate and loss of CRT stimulation.
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Acute exacerbations of congestive HF are be-
lieved to trigger ventricular arrhythmias through 
multiple potential mechanisms. The phenomenon 
described as mechano-electrical feedback causes an 
acute increase in filling pressure, which can lead to 
electrical instability [21, 22]. A temporal association 
between malignant ventricular arrhythmias and vol-
ume overload detected by OptiVol was already dem-
onstrated in two observational studies [23, 24]. The 
most likely reason for statistical non-significance of 
this parameter was the rare occurrence of malignant 
arrhythmias in the present patient cohort.
Predictive value of combined diagnostic  
algorithm in previous studies
Since the publication of PARTNERS HF trial 
several attempts have been made to develop a more 
reliable risk assessment model based on combined 
device based data. In the EVOLVO study some of 
the original PARTNERS HF criteria were used for 
remote monitoring of ICD patients, and a reduction 
in the rate of emergency admissions and urgent in-
office visits was demonstrated in the remote arm 
[25]. Gula et al. [26] acknowledging the limitations 
of the original PARTNERS HF criteria, worked 
out a novel diagnostic algorithm and validated 
it with convincing results in a post-hoc analysis 
of the RAFT trial. In phase 1 of  MORE-CARE 
randomized study delay from the device-detected 
events to clinical decision was shorter and fewer 
in-hospital visits were required in the remote moni-
tored group, however, the annual rate of all-cause 
hospitalizations could not be reduced [27]. None-
theless, in two recently published, randomized 
trials of OptiVol combined with remote monitoring 
no significant influence on HF-related hospitaliza-
tions, ICD shocks, or mortality was found [9, 28]. 
Also the second phase of the MORE-CARE study 
could not demonstrate that decision making guided 
by such remote-monitoring protocol exerts a posi-
tive impact on hard endpoints [27]. 
Limitations of the study
This single-center observational study is 
subject to all potential limitations of this kind of 
analysis. First of all, the limited number of in-
cluded patients should be highlighted. However, 
the average follow-up period (38 months) was 
longer with a high number of OptiVol alerts than 
in most of the previous reports. Furthermore, the 
presented findings can only help to exclude false 
positive cases from the current OptiVol alerts, as 
the study design was not aimed to identify HF 
episodes undetectable by the OptiVol algorithm. 
This study protocol consisted of at least 1 patient 
contact after an OptiVol alert. Since OptiVol alerts 
may occur 7–14 days before clinical symptoms of 
HF develop, repeated patient contact after the ini-
tial OptiVol alert could have possibly revealed some 
additional HF events. One important difference to 
the original PARTNERS HF study design should be 
also highlighted: Fluid Index ≥ 100 Ω-day has not 
been assigned in our analysis. Although the main 
idea of such a monitoring tool is to early identify 
risk patients as they reached an alert level, a scor-
ing system using higher fluid index values might 
signal an alarm too late. It should be also noted that 
Figure 3. Changes of device detected parameters in 
a patient with decompensated heart failure (heart rate 
variablity increases, while the patient status was wors-
ened because of an increase in average ventricular rate 
and loss of biventricular stimulation); AVR — average 
ventricular rate.
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recently a new OptiVol algorithm (OptiVol 2.0) was 
developed by the manufacturer for the calculation 
of the Fluid Index and the Reference Impedance 
[29]. In the presented patient population one part 
of the investigation used devices still working 
with OptiVol 1.0 (Concerto CRT-D, Concerto II 
CRT-D, Consulta CRT-D) the other part used the 
new algorithm (Viva Quad XT CRT-D, Protecta XT 
CRT-D, Brava Quad CRT-D).
Conclusions
A refined device diagnostic algorithm based 
on parameters of low activity level, high nocturnal 
HR, and suboptimal biventricular pacing could 
improve clinical reliability of OptiVol alerts in 
the presented patient cohort. These results are 
hypothesis generating, and hence this strategy of 
risk assessment should be prospectively tested in 
larger patient cohorts.
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